These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Schizophrenia: diverse approaches to a complex disease. Sawa A; Snyder SH Science; 2002 Apr; 296(5568):692-5. PubMed ID: 11976442 [TBL] [Abstract][Full Text] [Related]
43. Brain glycogen and its role in supporting glutamate and GABA homeostasis in a type 2 diabetes rat model. Sickmann HM; Waagepetersen HS; Schousboe A; Benie AJ; Bouman SD Neurochem Int; 2012 Feb; 60(3):267-75. PubMed ID: 22244844 [TBL] [Abstract][Full Text] [Related]
44. The role of cortical inhibition in the pathophysiology and treatment of schizophrenia. Daskalakis ZJ; Fitzgerald PB; Christensen BK Brain Res Rev; 2007 Dec; 56(2):427-42. PubMed ID: 17980435 [TBL] [Abstract][Full Text] [Related]
45. [Pathophysiology of schizophrenia and its impact on pharmacotherapy]. Widschwendter CG; Fleischhacker WW Fortschr Neurol Psychiatr; 2005 Nov; 73 Suppl 1():S32-7. PubMed ID: 16270242 [TBL] [Abstract][Full Text] [Related]
46. The neuronal pathology of schizophrenia: molecules and mechanisms. Reynolds GP; Harte MK Biochem Soc Trans; 2007 Apr; 35(Pt 2):433-6. PubMed ID: 17371293 [TBL] [Abstract][Full Text] [Related]
47. Monoaminergic synapses and schizophrenia: 45 years of neuroleptics. Bennett MR J Psychopharmacol; 1998; 12(3):289-304. PubMed ID: 10958257 [TBL] [Abstract][Full Text] [Related]
48. Direct receptor cross-talk can mediate the modulation of excitatory and inhibitory neurotransmission by dopamine. Lee FJ; Wang YT; Liu F J Mol Neurosci; 2005; 26(2-3):245-52. PubMed ID: 16012198 [TBL] [Abstract][Full Text] [Related]
49. [Biochemistry of schizophrenia and mechanism of action of neuroleptics]. Loo H; Cuche H; Sechter D Sem Hop; 1982 Dec; 58(44):2565-72. PubMed ID: 6130604 [TBL] [Abstract][Full Text] [Related]
50. Cellular and molecular neuropathology of schizophrenia: new directions from developmental neurobiology. Turner EE; Fedtsova N; Jeste DV Schizophr Res; 1997 Oct; 27(2-3):169-80. PubMed ID: 9416646 [TBL] [Abstract][Full Text] [Related]
51. Possible mechanisms of neurodegeneration in schizophrenia. Pérez-Neri I; Ramírez-Bermúdez J; Montes S; Ríos C Neurochem Res; 2006 Oct; 31(10):1279-94. PubMed ID: 17006758 [TBL] [Abstract][Full Text] [Related]
53. A two-process theory of schizophrenia: evidence from studies in post-mortem brain. Deakin JF; Simpson MD J Psychiatr Res; 1997; 31(2):277-95. PubMed ID: 9278190 [TBL] [Abstract][Full Text] [Related]
54. MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective. de Bartolomeis A; Iasevoli F; Tomasetti C; Buonaguro EF Mol Neurobiol; 2015 Dec; 52(3):1771-1790. PubMed ID: 25394379 [TBL] [Abstract][Full Text] [Related]
55. New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways. Perez SM; Lodge DJ Drug Des Devel Ther; 2014; 8():887-96. PubMed ID: 25061280 [TBL] [Abstract][Full Text] [Related]
57. Glutamate and dopamine in schizophrenia: an update for the 21st century. Howes O; McCutcheon R; Stone J J Psychopharmacol; 2015 Feb; 29(2):97-115. PubMed ID: 25586400 [TBL] [Abstract][Full Text] [Related]
58. A Novel Bio-Psychosocial-Behavioral Treatment Model in Schizophrenia. Kim YK; Choi J; Park SC Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28358303 [TBL] [Abstract][Full Text] [Related]
59. Epilepsy, schizophrenia, and the extended amygdala. Stevens JR Ann N Y Acad Sci; 1999 Jun; 877():548-61. PubMed ID: 10415670 [TBL] [Abstract][Full Text] [Related]
60. New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis. Yang AC; Tsai SJ Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28771182 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]